Celldex Therapeutics, Inc.
General ticker "CLDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.5B (TTM average)
Celldex Therapeutics, Inc. follows the US Stock Market performance with the rate: 54.1%.
Estimated limits based on current volatility of 2.9%: low 26.84$, high 28.45$
Factors to consider:
- Total employees count: 186 (+16.2%) as of 2024
- Top business risk factors: Need for additional capital, Strategic risks and growth management, Pandemic risks, Supply chain disruptions, Leadership loss
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [11.60$, 30.36$]
- 2025-12-31 to 2026-12-31 estimated range: [9.06$, 23.78$]
Financial Metrics affecting the CLDX estimates:
- Negative: with PPE of -10.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.73 <= 0.33
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -17.89 <= -14.38
Short-term CLDX quotes
Long-term CLDX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.36MM | $6.88MM | $7.02MM |
| Operating Expenses | $117.59MM | $161.43MM | $202.10MM |
| Operating Income | $-115.23MM | $-154.54MM | $-195.08MM |
| Non-Operating Income | $2.91MM | $13.11MM | $37.22MM |
| R&D Expense | $82.26MM | $118.01MM | $163.55MM |
| Income(Loss) | $-112.33MM | $-141.43MM | $-157.86MM |
| Profit(Loss)* | $-112.33MM | $-141.43MM | $-157.86MM |
| Stockholders Equity | $326.20MM | $429.17MM | $747.00MM |
| Assets | $352.74MM | $465.63MM | $792.34MM |
| Operating Cash Flow | $-103.73MM | $-107.29MM | $-157.78MM |
| Capital expenditure | $1.83MM | $1.82MM | $1.92MM |
| Investing Cash Flow | $89.94MM | $-105.78MM | $-290.13MM |
| Financing Cash Flow | $4.08MM | $218.46MM | $441.45MM |
| Earnings Per Share** | $-2.40 | $-2.92 | $-2.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.